Zobrazeno 1 - 8
of 8
pro vyhledávání: '"M. L. Penichet"'
Publikováno v:
Current Medicinal Chemistry-Central Nervous System Agents. 2:275-285
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3348a636d09215ddf2269a99350cfb1a
https://doi.org/10.2174/1568015023357905
https://doi.org/10.2174/1568015023357905
Publikováno v:
Human antibodies. 10(1)
Anti-HER2/neu therapy of human HER2/neu expressing malignancies such as breast cancer has shown only partial success in clinical trials. To expand the clinical potential of this approach, we have genetically engineered an anti-HER2/neu human IgG3 fus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::041f696f58f26f0dc0a2d4dd3d50a21c
https://pubmed.ncbi.nlm.nih.gov/11455061
https://pubmed.ncbi.nlm.nih.gov/11455061
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 163(1)
IL-12 is a heterodimeric cytokine with many actions on innate and cellular immunity that may have antitumor and antimetastatic effects. However, systemic administration of IL-12 can be toxic. Tumor-specific Abs provide a means to selectively target a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b9f240cfbcc086f36f3426107acc2d6b
https://pubmed.ncbi.nlm.nih.gov/10384123
https://pubmed.ncbi.nlm.nih.gov/10384123
Publikováno v:
Laboratory animal science. 49(2)
Expression of the HER2/neu proto-oncogene, a receptor-like transmembrane protein expressed at low levels on some normal cells, is markedly increased in a subset of human breast, colon, lung, and ovarian cancers. A humanized HER2/neu antibody has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4b30dcc9d9649458af12a2671955594b
https://pubmed.ncbi.nlm.nih.gov/10331548
https://pubmed.ncbi.nlm.nih.gov/10331548
Autor:
P M, Challita-Eid, C N, Abboud, S L, Morrison, M L, Penichet, K E, Rosell, T, Poles, S P, Hilchey, V, Planelles, J D, Rosenblatt
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 161(7)
The successful eradication of cancer cells in the setting of minimal residual disease may require targeting of metastatic tumor deposits that evade the immune system. We combined the targeting flexibility and specificity of mAbs with the immune effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::46edd06e46476fc06a6f7c4c757eb37d
https://pubmed.ncbi.nlm.nih.gov/9759898
https://pubmed.ncbi.nlm.nih.gov/9759898
Autor:
P M, Challita-Eid, M L, Penichet, S U, Shin, T, Poles, N, Mosammaparast, K, Mahmood, D J, Slamon, S L, Morrison, J D, Rosenblatt
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 160(7)
We describe the construction and characterization of an Ab fusion protein specific for the tumor-associated Ag HER2/neu linked to sequences encoding the extracellular domain of the B7.1 T cell costimulatory ligand. The Ab domain of the fusion molecul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::706ca38ff3df4c380d54e4a8444438e4
https://pubmed.ncbi.nlm.nih.gov/9531302
https://pubmed.ncbi.nlm.nih.gov/9531302
Publikováno v:
Human antibodies. 8(3)
Advances in genetic engineering and expression systems have led to a rapid progress in the development of immunoglobulins fused to other proteins. These 'antibody fusion proteins' have novel properties and include antibodies fused to the cytokine int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::118a152d5f1cfcf6eb9fa3af11e3b964
https://pubmed.ncbi.nlm.nih.gov/9322080
https://pubmed.ncbi.nlm.nih.gov/9322080
Autor:
Manuela Iezzi, Ml Penichet, P.-L. Lollini, C. De Giovanni, Luigi Aurisicchio, Giordano Nicoletti, Stefania Croci, Annalisa Murgo, Marina Fabbi, Annalisa Astolfi, Patrizia Nanni, Am Orengo, Augusto Amici, Agnese Antognoli, Lorena Landuzzi, Piero Musiani, Silvano Ferrini, A. Palladini
Publikováno v:
Human Gene Therapy. 20:453-464
The highly aggressive cancer syndrome of female mice carrying a p53 knockout allele and a rat HER-2/neu (Neu) transgene (BALB-p53Neu) can be prevented by a cell vaccine presenting three components: Neu, interleukin (IL)-12 production, and allogeneic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0736ccdfc56945d6b6578a20573b8bd6
https://doi.org/10.1089/hum.2008.172
https://doi.org/10.1089/hum.2008.172